MATCH Biosystems, MIKROBIOMIK, and Oniria Therapeutics have been selected for the second edition of the Mentoring Program in Market Access for SMEs by AseBio and Alira Health
The three companies, members of AseBio, work every day to improve treatments and patients' lives through rapid diagnosis of infectious diseases, intestinal microbiota, and precision oncology.
Last January, AseBio and Alira Health, a global advisory and clinical research firm, launched the second edition of their Mentoring Program in Market Access for SMEs. An initiative that, following the success achieved with its first edition, aims to continue supporting and driving market access for innovation from small Spanish biotechnology companies.
"The launch of the second edition of the Mentoring Program in Market Access for Spanish biotechnological startups demonstrates our commitment to the sector at the national level. The program assists these companies in their early stage to identify gaps in their market access plans and strategically prioritize milestones with the greatest impact on their business. A team of high-level experts will provide these companies with invaluable assistance as they develop launch strategies for their target markets," states Chus Castillo, Partner Consulting Iberia at Alira Health.
"The companies participating in the first edition have conveyed a high level of satisfaction to us. They assure us that the experience has allowed for the improvement of their projects, as well as the identification of areas that needed enhancement to boost their products. Programs of this kind are fundamental to drive the potential of biotechnological innovation and strengthen innovation in our country," affirms Ion Arocena, General Director of AseBio.
The three companies, members of AseBio, that have been selected are MATCH Biosystems, MIKROBIOMIK, and Oniria Therapeutics. They will have access to an experienced team of market access consultants who will guide them in improving their value proposition and help navigate the ecosystem and properly define their market access needs.
The program consists of a 40-hour service package including an initial meeting, background analysis, orientation session for financing applications, application reviews, and additional consultations.
MATCH Biosystems
MATCH Biosystems focuses on the development, production, and commercialization of in vitro diagnostic (IVD) kits for the rapid diagnosis of infectious diseases in critically ill patients, especially sepsis.
Their initial development, focused on Invasive Fungal Infections (including 100% of cases of Invasive Candidiasis), is a comprehensive diagnostic solution that accelerates diagnosis from 2-5 days to 2-5 hours, with >95% reliability, improving healthcare and reducing costs by >30K$/patient.
"From MATCH, we are convinced that it is a 'win-win-win' collaboration. During 2022-2023, the teams from Alira Health and MATCH worked together on the opportunity analysis and market study phase within the infectious disease Dx sector. This first collaboration had a very satisfactory outcome for both parties, representing validation in the project direction for MATCH, and for Alira Health, generating a new success story," explains their CEO, Adrián H. Teruel.
"With this program, we hope that the strategic capabilities of our team will complement the deep expertise of the Alira Health team, to penetrate the target Dx market swiftly and effectively. And thereby, generate the highest priority 'win', the 'win' for clinicians and patients, so that they can have access to the innovative diagnostic solutions developed by MATCH."
MIKROBIOMIK
MIKROBIOMIK is a biopharmaceutical company born for the research, development, production, and commercialization through third parties of drugs based on the human microbiome. Founded in 2018, MIKROBIOMIK aspires to be the first global company to market in the EU the first biological drug based on intestinal microbiota for the indication of Clostridium difficile recurrence, through the administration of MBK-01 (four capsules of lyophilized fecal microbiota) in a single dose.
"For Mikrobiomik, this opportunity has immense value, as we face the challenge of being the first global company to market in the EU the first biological drug based on intestinal microbiota, so our market access route is yet to be defined, after our leading product MBK-01 has been classified as a new active substance by the EMA (European Medicines Agency), allowing us to proceed through the centralized pathway," shared the company. "We appreciate AseBio and Alira Health for their great support through this excellent program, accompanying us on this complex and exciting journey to reach the goal with a first-in-class."
Oniria Therapeutics
Oniria Therapeutics is a biopharmaceutical company with the mission of developing drugs in the field of precision oncology and specifically focused on cancer persistence.
Their product, ONR-358, is classified as a demethylating epigenetic agent and has already demonstrated efficacy in pre-clinical models of colon cancer, melanoma, and acute myeloid leukemia. Its mechanism of action focuses on activating the demethylating enzyme TET2, allowing the elimination of persistent tumor cells responsible for patients' progression to advanced stages of cancer. It is a fully specific drug, carrying, among other advantages, lower toxicity.
"The collaboration with AseBio - Market Access Mentoring Program for SMEs will be key for the investment round that Oniria Therapeutics has begun to raise," concludes Esther Riambau, CEO of Oniria Therapeutics.